Company Filing History:
Years Active: 2023
Title: Inventor Susan Flavin: Pioneering New Treatments for Psoriasis
Introduction: Susan Flavin, based in Spring City, Pennsylvania, is an innovative inventor recognized for her contributions to the field of dermatology. With one patent to her name, she is at the forefront of developing safe and effective methods for treating psoriasis, a condition that affects millions of individuals worldwide.
Latest Patents: Flavin's patent, titled "Safe and effective method of treating psoriasis with anti-IL-23 specific antibody," outlines a groundbreaking approach to psoriasis treatment. The method involves administering an IL-23 specific antibody, such as guselkumab, in clinically proven safe and effective doses. Notably, patients treated with this method can achieve significant outcomes such as PASI90, PASI100, or IGA scores of 0 or 1 at various time points including 16, 24, 32, 40, and 48 weeks after the initial treatment. Moreover, her approach has demonstrated higher efficacy compared to treatments using secukinumab antibodies.
Career Highlights: Susan Flavin has made significant strides in her career at Janssen Biotech, Inc., where she further explores the potential of anti-IL-23 specific antibodies in treating inflammatory conditions. Her dedication to research and development in this field highlights her role as a leading inventor contributing to medical advancements.
Collaborations: Throughout her journey, she has collaborated with notable coworkers such as Julianty Angsana and Patrick Branigan. These partnerships have enriched her work, contributing to the enhanced understanding and exploration of innovative treatments for psoriasis and other inflammatory diseases.
Conclusion: Susan Flavin stands out as a pioneering inventor in the field of dermatology, with her patent contributing significantly to the treatment of psoriasis. Her innovative approach not only offers hope to patients but also reflects the importance of continued research and collaboration in the medical field. As she continues to work at Janssen Biotech, Inc., the future of psoriasis treatment looks promising under her guidance.